<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-144078</identifier>
<setSpec>1139-6202</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Luque del Moral, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Pharm. care Esp;17(4): 475-481, 2015. tab</dc:source>
<dc:identifier>ibc-144078</dc:identifier>
<dc:title xml:lang="es">La forma farmac√©utica un factor a valorar en el SFT</dc:title>
<dc:subject>^d14538^s22000</dc:subject>
<dc:subject>^d50495^s22057</dc:subject>
<dc:subject>^d14538^s22020</dc:subject>
<dc:subject>^d19283</dc:subject>
<dc:subject>^d11756</dc:subject>
<dc:subject>^d28219</dc:subject>
<dc:subject>^d10786</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28480</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d14538^s22073</dc:subject>
<dc:subject>^d78^s22073</dc:subject>
<dc:subject>^d7140^s22057</dc:subject>
<dc:subject>^d19369</dc:subject>
<dc:subject>^d7140^s22016</dc:subject>
<dc:subject>^d11016</dc:subject>
<dc:subject>^d11795</dc:subject>
<dc:subject>^d53262</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d50495^s22016</dc:subject>
<dc:subject>^d11253</dc:subject>
<dc:type>article</dc:type>
<dc:date>201500</dc:date>
</metadata>
</record>
</ibecs-document>
